- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04944901
28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder
Randomized, Double-blind, Placebo-controlled, 28-Day Daily-dose Crossover Study of the Safety and Tolerability of SB-121 (Lactobacillus Reuteri With Sephadex® and Maltose) in Subjects, Ages 15 to 45 Years, Diagnosed With Autistic Disorder
SB-121 is being developed for use in the treatment of autistic disorder (AD).
This study is a multiple-dose, randomized, double-blind, placebo-controlled, cross-over single-site Phase I study.
The primary objective is to evaluate the safety and tolerability of multiple doses of SB-121 in subjects ages 15 to 45 years with AD.
Additionally, multiple measures of AD, as well as mechanistic biomarkers, will be assessed in order to inform later stage trials.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject/parent (or authorized designee) has provided written informed consent for the study.
- Subject is ≥15 and ≤45 years of age at the time of enrollment.
- Diagnosis of autistic disorder (AD) as confirmed by the gold standard clinical interview using Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 criteria and administration of the Autism Diagnostic Observation Schedule-2.
- Subject, if female and of childbearing potential, is not lactating or pregnant.
- Subject, if female, is either not of childbearing potential or is practicing an acceptable effective method of birth control.
- Subject is willing to comply with all study requirements (including the requirements for stool sampling and biobanking) and to return to the study facility for the follow-up evaluations, as required.
Exclusion Criteria:
- Subject has known allergy or significant adverse reaction to L reuteri, Sephadex®, maltose, or related compounds.
- Subject has previously had GI surgery, intestinal obstruction, Clostridium difficile infection or diverticulitis.
- Subject has travelled outside of the USA in the 30 days prior to screening.
- Subject has had a diarrheal illness in 30 days prior to screening.
- Subject currently has a fever or active/uncontrolled gastrointestinal (GI) symptoms (e.g., nausea, vomiting, diarrhea, constipation, abdominal distention, abdominal pain/cramps, flatulence) or has had these within 14 days prior to screening. If the GI symptoms are stable, in the opinion of the investigator, the subject can be enrolled.
- Subject has any immunological/autoimmune disorder including, but not limited to, systemic lupus erythematosis, rheumatoid arthritis, Sjögren's syndrome, inflammatory bowel disease, or immunoglobulin-deficiency disorder, that would increase the risk to the subject or interfere with the evaluation of SB-121.
- Subject has a documented history of human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C
- Subject has implanted prosthetic devices including prosthetic heart valves.
Subject has taken, or is taking, any of the following prohibited medications:
- A proton pump inhibitor within 2 weeks prior to screening
- Use of supplemental probiotics within 2 weeks prior to screening except for yogurt
- Current use of immunosuppressive medications, including corticosteroids
- Treatment with monoclonal antibodies within 4 weeks prior to screening
- Systemic antibiotics within 2 weeks prior to screening
- Subject has diabetes mellitus or is prediabetic.
- Subject has received any IP (or investigational device) within 30 days prior to screening.
Subject has any of the following laboratory test results at Screening:
- An absolute neutrophil count of <1.5 × 10^9/L
- alanine aminotransferase or aspartate aminotransferase >1.5 × upper limit normal (ULN), total bilirubin >1.5 × ULN (subjects with known Gilbert's Syndrome can be included)
- serum creatinine >1.5 × ULN
- any other abnormal laboratory test that is clinically significant in the judgment of the investigator.
- Subject has an unstable medical condition or is otherwise considered unreliable or incapable, in the opinion of the investigator, of complying with the requirements of the protocol.
- Subject tests positive for drugs of abuse in a urine drug screen at screening.
- Subject has a history of alcohol abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SB-121
One dose of SB-121 daily for 28 days according to the treatment group to which they are allocated. Administration: Oral |
SB-121 is a formulation of L. reuteri
|
Placebo Comparator: Placebo
One dose of placebo daily for 28 days according to the treatment group to which they are allocated. Administration: Oral |
Placebo oral formulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Event of Special Interest (AESIs) and Adverse Events (AEs) Leading to Discontinuation
Time Frame: Approximately 98 days
|
Adverse event of special interest (AESIs) and adverse events (AEs) leading to discontinuation from the study are presented. Treatment Period 1: 2 participants reported 4 events in the SB-121 group and 3 participant reported 6 events in the placebo group. Treatment Period 2: 1 participant reported 3 events in the SB-121 group and 1 participant reported 4 events in the placebo group. |
Approximately 98 days
|
Sephadex Microspheres in the Stool
Time Frame: Period 1: Days 1 (pre-dose), 28 and 35; Period 2: Days 28 and 42 (period = 28 days and 14 days wash-out)
|
The presence of Sephadex microspheres in the stool was assessed. The number of participants with data available at each stage are presented. |
Period 1: Days 1 (pre-dose), 28 and 35; Period 2: Days 28 and 42 (period = 28 days and 14 days wash-out)
|
Symptomatic Bacteremia With Positive L. Reuteri Identification
Time Frame: Approximately 98 days
|
The presence of symptomatic bacteremia with positive L. reuteri identification was assessed and none of the participants in either group showed any clinical features of suspected bacteremia in this study.
|
Approximately 98 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percent Change From Baseline in Biomarkers: Tumor Necrosis Factor-α
Time Frame: Day -28 to Day 0, Period 1: Day 28; Period 2: Days 1 (pre-dose) and 28 (period = 28 days and 14 days wash-out)
|
Mean (standard deviation) percent changes from baseline in tumor necrosis factor-α
|
Day -28 to Day 0, Period 1: Day 28; Period 2: Days 1 (pre-dose) and 28 (period = 28 days and 14 days wash-out)
|
Mean Percent Change From Baseline in Biomarkers: Serum High-sensitivity C-reactive Protein (Hs-CRP)
Time Frame: Day -28 to Day 0, Period 1: Day 28; Period 2: Days 1 (pre-dose) and 28 (period = 28 days and 14 days wash-out)
|
Mean (standard deviation) percent change from baseline in serum high-sensitivity C-reactive protein (hs-CRP)
|
Day -28 to Day 0, Period 1: Day 28; Period 2: Days 1 (pre-dose) and 28 (period = 28 days and 14 days wash-out)
|
Mean Percent Change From Baseline in Biomarkers: Stool Biomarkers, Fecal Calprotectin
Time Frame: Period 1: Days 1 (pre-dose), 28 and 35; Period 2: Days 28 and 35 (period = 28 days and 14 days wash-out)
|
Mean (standard deviation) percent change from baseline in stool biomarkers, fecal calprotectin. The number of participants with data available are presented. |
Period 1: Days 1 (pre-dose), 28 and 35; Period 2: Days 28 and 35 (period = 28 days and 14 days wash-out)
|
Mean Percent Change From Baseline in Biomarkers: Stool Biomarkers, Fecal Lactoferrin
Time Frame: Period 1: Days 1 (pre-dose), 28 and 35; Period 2: Days 28 and 35 (period = 28 days and 14 days wash-out)
|
Mean (standard deviation) percent change from baseline in stool biomarkers, fecal lactoferrin. The number of participants with data available are presented. |
Period 1: Days 1 (pre-dose), 28 and 35; Period 2: Days 28 and 35 (period = 28 days and 14 days wash-out)
|
Mean Percent Change From Baseline in Biomarkers: Plasma Oxytocin
Time Frame: Day -28 to Day 0, Period 1: Day 28; Period 2: Days 1 and 28 (period = 28 days and 14 days wash-out)
|
The mean (standard deviation) percent changes from baseline in plasma oxytocin.
|
Day -28 to Day 0, Period 1: Day 28; Period 2: Days 1 and 28 (period = 28 days and 14 days wash-out)
|
Mean Percent Change From Baseline in Biomarkers: Plasma Vasopressin
Time Frame: Day -28 to Day 0, Period 1: Day 28; Period 2: Days 1 (pre-dose) and 28 (period = 28 days and 14 days wash-out)
|
Mean (standard deviation) percent changes from baseline in plasma vasopressin levels
|
Day -28 to Day 0, Period 1: Day 28; Period 2: Days 1 (pre-dose) and 28 (period = 28 days and 14 days wash-out)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Craig Erickson, MD, University of Cincinnati
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SBI-SB121-20-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autistic Disorder
-
Mahidol UniversityCompleted
-
Hadassah Medical OrganizationTerminated
-
Fundatia Bio-ForumSpitalul AngiomedicaCompletedAutistic Spectrum DisorderRomania
-
University of JazanCompletedAutistic Spectrum DisorderSaudi Arabia
-
Assistance Publique - Hôpitaux de ParisHopital Universitaire Robert-Debre; Henri Mondor University Hospital; Fondation... and other collaboratorsCompleted
-
Sutter Medical FoundationCompleted
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Hospital Parc Taulí, SabadellUnknownSexual Behavior | Adolescent Development | Autistic Disorders Spectrum | Sexual InadequacySpain
-
Université de Reims Champagne-ArdenneNot yet recruitingImpact of Mixed Reality Training on Motor Skills in Children With Autistic Spectrum Disorder (RAMAu)Autistic Spectrum Disorder
-
Addis Ababa UniversityCompletedAutistic Spectrum DisorderEthiopia
Clinical Trials on SB-121
-
Valeant PharmaceuticalsUnknown
-
REGENXBIO Inc.Active, not recruitingMucopolysaccharidosis Type II (MPS II)United States, Brazil
-
Valeant PharmaceuticalsUnknown
-
Vertex Pharmaceuticals IncorporatedActive, not recruitingCystic FibrosisUnited States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
-
Vertex Pharmaceuticals IncorporatedActive, not recruitingCystic FibrosisUnited States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited States
-
University of MinnesotaRecruitingCardiovascular Diseases | Type 2 DiabetesUnited States
-
Allarity TherapeuticsAmarex Clinical Research; Alcedis GmbHRecruitingAdvanced Ovarian CancerUnited Kingdom, United States
-
Allarity TherapeuticsAmarex Clinical ResearchRecruiting